![](https://i.imgur.com/CLvY2jA.png")
President Joe Biden’s recent bout with COVID-19 and his subsequent rebound case has brought attention to the treatment he used—Pfizer’s Paxlovid.
Now the FDA is questioning the company about the highly touted oral antiviral for those who are infected and considered at high risk to progress to a severe form of the virus.
Two recent studies show that COVID rebound happens to 27% of those who are infected but suggest that is more prevalent and pronounced among users of Paxlovid.
Pfizer reported Paxlovid sales of $8.1 billion for the second quarter and expects revenue from the drug to reach $22 billion this year.
https://www.fiercepharma.com/pharma/fda-...e-paxlovid
Now the FDA is questioning the company about the highly touted oral antiviral for those who are infected and considered at high risk to progress to a severe form of the virus.
Two recent studies show that COVID rebound happens to 27% of those who are infected but suggest that is more prevalent and pronounced among users of Paxlovid.
Pfizer reported Paxlovid sales of $8.1 billion for the second quarter and expects revenue from the drug to reach $22 billion this year.
https://www.fiercepharma.com/pharma/fda-...e-paxlovid
